News

GSK falls as blood cancer drug likely headed for US rejection
(Reuters) -GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel ...
STAT2h
Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
GSK falls Friday, underperforms market
GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.
Global Stocks in the Spotlight: Alibaba, Saab, Burberry, GSK
The Swedish defense company posted better-than-expected earnings and [raised its annual sales guidance]( ...
FDA approves GSK’s prefilled syringe presentation of Shingrix
Administering Shingrix previously required combining a lyophilised antigen with a liquid adjuvant from two separate vials.
pharmaphorum8h
GSK's growth plans dented by Blenrep setback
The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...
Fierce Biotech2d
GSK telegraphs 'very limited number' of job cuts amid R&D investment spree
With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...
Fierce Pharma23h
FDA advisors spurn GSK’s Blenrep comeback dreams on safety, trial concerns
On a quest to bring its multiple myeloma antibody-drug conjugate (ADC) Blenrep back to the U.S. | Members of the FDA's Oncologic Drugs Advisory Committee voiced concerns with ocular toxicity side ...